Vir Biotechnology, Inc. $VIR Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 144.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 95,927 shares of the company’s stock after purchasing an additional 56,655 shares during the quarter. Quantinno Capital Management LP’s holdings in Vir Biotechnology were worth $860,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Raymond James Financial Inc. bought a new stake in shares of Vir Biotechnology in the 2nd quarter worth approximately $35,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Vir Biotechnology by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after purchasing an additional 1,390 shares during the period. UMB Bank n.a. lifted its stake in shares of Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after acquiring an additional 6,597 shares during the period. CWM LLC lifted its position in Vir Biotechnology by 23.0% in the fourth quarter. CWM LLC now owns 8,804 shares of the company’s stock worth $53,000 after purchasing an additional 1,646 shares during the period. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Vir Biotechnology in the fourth quarter valued at $60,000. Institutional investors own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. HC Wainwright reaffirmed a “buy” rating on shares of Vir Biotechnology in a research note on Monday, August 10th. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Morgan Stanley set a $25.00 price target on Vir Biotechnology in a research note on Thursday, August 6th. Finally, Leerink Partners increased their target price on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $20.62.

Vir Biotechnology Stock Performance

NASDAQ:VIR opened at $9.39 on Tuesday. Vir Biotechnology, Inc. has a 52-week low of $4.25 and a 52-week high of $11.66. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -5.05 and a beta of 1.66. The firm’s 50-day moving average is $9.32 and its 200-day moving average is $9.14.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.33 by $0.14. The firm had revenue of $238.95 million during the quarter, compared to analysts’ expectations of $135.88 million. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The company’s revenue for the quarter was up 19582.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.80) EPS. Equities analysts predict that Vir Biotechnology, Inc. will post -1.84 EPS for the current year.

Insider Transactions at Vir Biotechnology

In related news, Director Janet Napolitano sold 3,200 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the transaction, the director owned 21,216 shares of the company’s stock, valued at $200,491.20. This represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is owned by company insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.